Advent of the HIF Stabilizers: Key Considerations for Anemia of CKD Care
Credit(s): 1.00 (60 min)
Release Date: Jan 17, 2020
Expiration Date: Jan 17, 2021
CME / AMA PRA Category 1 Credit™
MOC / ABIM MOC Part 2 Credit
CNE / Nursing Contact Hours
MIPS Improvement Activity Under MACRA
Hypoxia-inducible factor (HIF) stabilizers are a new class of drugs in late-stage trials that may soon shift the balance of treatment for anemia of chronic kidney disease (CKD). These oral agents are well-tolerated by patients, unlike red-cell transfusions and conventional erythropoiesis-stimulating agents (ESAs). In addition, HIF stabilizers, unlike ESAs, are able to increase hemoglobin (Hgb) levels irrespective of iron supplementation or inflammatory status.
In light of the potential of these groundbreaking emerging therapies, it is critical that nephrology clinicians are aware of the HIF stabilizers and their safety and efficacy data. This educational activity, “Advent of the HIF Stabilizers: Key Considerations for Anemia of CKD Care,” will help participants evaluate the risks and benefits of conventional anemia of CKD treatments, as well as the latest evidence and potential roles of the HIF stabilizers, so that, upon approval, they can be properly incorporated into patient care.
Welcome and Introduction
Setbacks with Conventional Therapies for Anemia of CKD
Understanding the Potential of HIF Stabilizers in Anemia of CKD Care
Q&A Session and Concluding Remarks
This activity is intended for nephrologists and nurse practitioners who diagnose and manage patients with anemia of CKD.
This program is designed to address the following National Academy of Medicine (NAM) competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to:
Evaluate the risks and benefits of ESAs, iron, and blood transfusions in anemia of CKD care
Assess the most up-to-date evidence and potential roles of the HIF stabilizers in clinical development for the management of anemia of CKD
Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Physicians – Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Bruce Spinowitz, MD, FACP
Associate Director, Nephrology
Vice Chairman, Medicine
New York Presbyterian Queens
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY
Bruce Spinowitz, MD, FACP is Vice Chairman of the Department of Medicine at New York Hospital Queens and Associate Director of Nephrology and Dialysis Services at the hospital’s Trude Weishaupt Memorial Satellite Dialysis Center. He is also a Professor of Clinical Medicine at the Weill Medical College of Cornell University.
He received his medical degree at the New York University School of Medicine and his internal medicine and nephrology training at Bellevue/NYU Hospital in New York City. Following his training he was Associate Director of Dialysis at Bellevue Hospital before joining Nephrology Associates PC in 1979.
He has worked with numerous pharmaceutical companies during the last 25 years, as an investigator and advisor to industry, and has published more than 70 peer-reviewed articles in the nephrology literature. His research activities have been in anemia, iron replacement, hyperphosphatemia, diabetic nephropathy, and hyperkalemia. He has been named to New York Magazine’s listing of super doctors consistently over the past 10 years and received the 2014 Nephrologist of the Year award from the American Kidney Fund.
Jay Wish, MD, FASN
Professor of Clinical Medicine,
Chief Medical Officer for Dialysis
Indiana University Health
Jay Wish, MD, FASN is Professor of Clinical Medicine at the Indiana University School of Medicine in Indianapolis and Chief Medical Officer for Dialysis at Indiana University Health. He is currently the Medical Director at dialysis facilities in Indianapolis and Muncie, IN. Dr. Wish is Past President of the National Forum of ESRD Networks and has been an advisor to the Centers for Medicare and Medicaid Services (CMS) on quality improvement issues in dialysis. He served on the Board of Directors of the Renal Physicians Association and the American Association of Kidney Patients and was the recipient of the latter’s Visionary Award in 2005.
Dr. Wish is Vice Chairman of the Editorial Advisory Board for Nephrology News & Issues and serves on the Editorial Boards of the Journal of the American Society of Nephrology and Clinical Journal of the American Society of Nephrology. He has had more than 100 articles, reviews, and book chapters published, particularly in the areas of ESRD quality oversight/improvement, accountability, anemia management, and vascular access.
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
MIPS CREDIT DESIGNATION
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Rockpointe Corporation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSING CREDIT DESIGNATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURES OF CONFLICTS OF INTEREST
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Faculty and Steering Committee Disclosures
The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Bruce Spinowitz, MD, FACP: Consultant: Akebia, AstraZeneca; Research Grant: Akebia, Fibrogen, GlaxoSmithKline
Jay Wish, MD, FASN: Consultant: Akebia, AstraZeneca, Otsuka, Zydus
Steven C. Borkan, MD (BUSM Course Director): Nothing to disclose
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Nicolle Rochino, PharmD, RPh; Blair St. Amand; Elizabeth Drury; Natalie Sanfratello, MPH; PIM Planners and Managers: Nothing to disclose
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing an HTML5 video.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 50% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
Developed in collaboration with
Jointly provided by
Supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
X-Linked Hypophosphatemia: Improving Clinician Awareness and Management
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.